HK Stock Market Move | JUNSHI BIO(01877) Rises Over 4% on Strategic Cooperation with Meijie Medical to Explore "Multimodal Drug-Device Combination" in Tumor Treatment

JUNSHI BIO (01877) rose over 4%, up 4.03% as of press time, at HK$19.09, with a turnover of HK$23.2684 million. On the news front, according to JUNSHI BIO's official WeChat account, the company announced that it has recently formally signed a strategic cooperation agreement with Meijie Medical. The two parties will carry out comprehensive strategic cooperation around core directions such as "multimodal thermophysical immune regulation platform technology combined with drugs for clinical research, and new drug target exploration," leading tumor treatment into a new era of "multimodal drug-device combination." The focus of this cooperation is to break traditional industry boundaries, systematically integrate local precision intervention with systemic immune activation, and build a new treatment model of "interventional immunity." The two parties will focus on the launch of joint clinical research and data accumulation, clarifying the efficacy and safety characteristics of the combination regimen in target indications; exploring the feasibility of obtaining regulatory recognition for the "drug-device combination" regimen and forming a replicable registration and commercialization path; and hoping to expand this model to more tumor types and treatment combinations, promoting "drug-device combination" to become one of the standard options for tumor treatment, while also exploring the possibility of extending to overseas markets.